Cabergoline
Christopher P. Rains, Harriet M. Bryson, Andrew Fitton · Drugs · 1995
Cited by 142 works. doi:10.2165/00003495-199549020-00009
Authors
References
- Pituitary Magnetic Resonance Imaging in Normal Human Volunteers: Occult Adenomas in the General Population
- A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
- Dopamine Agonists and Pituitary Tumor Shrinkage
- Long-Lasting Prolactin-Lowering Effect of Cabergoline, A New Dopamine Agonist, in Hyperprolactinemic Patients
- Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
- Effectiveness and Tolerability of Long Term Treatment with Cabergoline, a New Long-Lasting Ergoline Derivative, in Hyperprolactinemic Patients*
- Surveillance of Bromocriptine in Pregnancy
- Cabergoline in the long-term therapy of hyperprolactinemic disorders
- Cabergoline: Long-Acting Oral Treatment of Hyperprolactinemic Disorders
- Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study